Articles published in Journal of Pharmacogenomics & Pharmacoproteomics have been cited by esteemed scholars and scientists all around the world. Journal of Pharmacogenomics & Pharmacoproteomics has got h-index 12, which means every article in Journal of Pharmacogenomics & Pharmacoproteomics has got 12 average citations.
Following are the list of articles that have cited the articles published in Journal of Pharmacogenomics & Pharmacoproteomics.
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total published articles |
30 | 56 | 30 | 30 | 13 | 4 | 7 | 15 | 13 | 20 | 25 | 12 | 35 | 13 | 2 |
Research, Review articles and Editorials |
0 | 6 | 2 | 4 | 1 | 1 | 6 | 14 | 12 | 17 | 25 | 12 | 34 | 7 | 2 |
Research communications, Review communications, Editorial communications, Case reports and Commentary |
30 | 50 | 28 | 8 | 2 | 0 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
Conference proceedings |
0 | 0 | 0 | 0 | 0 | 0 | 35 | 102 | 83 | 47 | 82 | 0 | 0 | 0 | 0 |
Citations received as per Google Scholar, other indexing platforms and portals |
35 | 55 | 58 | 71 | 61 | 49 | 63 | 48 | 72 | 63 | 23 | 8 | 6 | 0 | 0 |
Journal total citations count | 613 |
Journal impact factor | 2.31 |
Journal 5 years impact factor | 3.74 |
Journal cite score | 4.86 |
Journal h-index | 12 |
Mutation in the CAV3 gene causes partial caveolin-3 deficiency and persistent elevated levels of serum creatine kinase
Next-generation sequencing to diagnose muscular dystrophy, rhabdomyolysis, and hyperCKemia
Differential diagnosis of HyperCKemia
Interaction potential between clarithromycin and individual statins—A systematic review
Pharmacogenomics and tailored polypharmacy: an 80-year-old lady with rosuvastatin-associated rhabdomyolysis and maprotiline-related Ogilvie's syndrome
From a fish tank injury to hospital haemodialysis: the serious consequences of drug interactions
An overview of statin-induced myopathy and perspectives for the future
Genomic variations affecting biological effects of statins
Polymorphisms in CYP450 genes and the therapeutic effect of atorvastatin on ischemic stroke: a retrospective cohort study in Chinese population
Clinical features related to statin?associated muscle symptoms
A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention
Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects
Cardiovascular Pharmacogenomics: Does It Matter If You're Black or White?
The role of ADME pharmacogenomics in early clinical trials: perspective of the Industry Pharmacogenomics Working Group (I-PWG)
Genetic and Clinical Factors Are Associated With Statin?Related Myotoxicity of Moderate Severity: A Case–Control Study
Individual and combined associations of genetic variants in CYP3A4, CYP3A5, and SLCO1B1 with simvastatin and simvastatin acid plasma concentrations
All for statins and statins for all; an update
Statins and the neuromuscular system: a neurologist's perspective
The risk of hepatotoxicity, new onset diabetes and rhabdomyolysis in the era of high-intensity statin therapy: does statin type matter?
The future of pharmaceutical manufacturing in the context of the scientific, social, technological and economic evolution